You are about to leave an AbbVie Canada site, a Web site maintained by AbbVie Corporation.
This link is provided for your convenience only. AbbVie Corporation takes no responsibility for the content of any Web site maintained by any third party and makes no representation as to the accuracy or completeness of any information contained on this or any subsequent link.
Below is a list of all AbbVie clinical trials in Canada that you or someone you know might be interested in joining. Find what you’re looking for by using the filters to narrow down the results. You can also see the full list of conditions in which AbbVie deals here.
This is a multi center, randomized, double-blind, placebo-controlled phase 2 study in subjects with moderately to severely active rheumatoid arthritis on backgroundmethotrexate who have failed anti-Tumor Necrosis Factor (TNF) biologic therapy.
Recruitment Status:Study is now Completed Canada site Cancelled
A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical RemissionRheumatoid ArThritis (RA) Subjects (PREDICTRA).
The purpose of this study is to describe the impact of treatment with adalimumab on work related productivity and economic burden in patients with Rheumatoid Arthritis (RA) treated in Canada.
A Canadian study to evaluate early use of adalimumab after methotrexate failure in early rheumatoid arthritis. The study hypothesis will verify if adalimumab effectively reduces joint damage in more patients when introduced earlier than in current practice.
The REACH study is conducted to describe the clinical effectiveness of adalimumab (HUMIRA) in subjects with moderately to severely active Rheumatoid Arthritis (RA) that are receiving anti-rheumatic treatments including adalimumab.
The comparison of safety and efficacy of upadacitinib versus abatacept in participants with rheumatoid arthritis on a stable background conventional synthetic Disease Modifying Anti-Rheumatic Drug (csDMARD) who have an inadequate response or intolerance to biologic DMARDs.
To give you the best possible user experience, this site uses cookies and by continuing to use this site, you agree that this site saves them on your devices for analytics purposes and to remember your preferences. For more information, please read our terms of use and our Privacy policy.